BLU — BELLUS Health Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $1.87bn
- $1.56bn
- $0.02m
Brief: Bellus Health Inc Files For Shelf Of Up To $250 Mln Common Shares– SEC Filing
Brief: Bellus Health Announces First Patient Dosed In Its Phase 2 Blueprint Trial Of Blu-5937
Brief: BELLUS Health Announces First Patient Dosed in its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
Brief: BELLUS Health Appoints Ramzi Benamar As Chief Financial Officer
Brief: BELLUS Health Reports Q3 Loss Per Share $0.09
Brief: Point72 Asset Management Reports Passive Stake Of 7.9% In Bellus Health As Of October 22 - SEC Filing
Brief: Bellus Health Announces Pricing Of $35 Mln Public Offering In Canada And United States
Brief: Bellus Health Announces Launch Of A Public Offering Of Common Shares In Canada And United States
Brief: Bellus Health Reports Qtrly Loss Per Share $0.14
NASDAQ RESUMED AT 01:47 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:42 PM
NASDAQ RESUMED AT 07:50 AM
NASDAQ RESUMED AT 07:30 AM
Brief: Bellus Health Announces Topline Results From Phase 2 Relief Trial Of Blu-5937 For Treatment Of Refractory Chronic Cough
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:00 AM
Brief: Bellus Health Reports Q1 Net Loss Of $0.18 Per Share
Brief: Bellus Health Announces Completion Of Dosing In Phase 2 Relief Trial With BLU-5937 For Treatment Of Refractory Chronic Cough
BELLUS Health: Rises on deal to acquire IP rights to cough drug
Brief: Bellus Health Inc - Bellus To Own 100% Of BLU-5937 And Related P2X3 Antagonists Intellectual Property With No Future Payments Due